When will Acemini be launched? Has it been launched in China?

Asciminib (scemblix/asciminib) was approved for marketing by the US FDA in 2021. Asciminib is a kinase inhibitor used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) is in the chronic phase (CP) and has been treated with two or more tyrosine kinase inhibitors (TKIs). It is also used to treat T315I mutant chronic myelogenous leukemia patients with Ph+ chronic myelogenous leukemia. Aximini has not yet been launched in China, but there is a version officially launched in Laos. The retail price of Lucius Pharmaceuticals in Laos40mg60tablets4 is more than a thousand.

According to the results of animal studies and its mechanism of action, taking aximinil by pregnant women can cause harm to the fetus. In animal reproduction studies, administration of aceminil to pregnant rats and rabbits during organogenesis resulted in adverse developmental outcomes, including maternal exposure (AUC) equal to or less than that seen in patients at recommended doses - fetal mortality and malformations. Inform pregnant women and women of the potential reproductive risk to the fetus if asiminid is used during pregnancy or if the patient becomes pregnant while taking asiminid. Verify the pregnancy status of females of reproductive potential before initiating treatment with aceminib. Females of childbearing potential should use effective contraception during treatment with Asiminib and for 1 week after the last dose. If you want to get more high-quality information, you can contact YaoDe. YaoDe will do its best to learn more about high-quality overseas drugs for you.

xa0